Press Release 17.04.2015
17 April 2015
RELEASED FRIDAY, APRIL 17, 2015 AT 15:00 (BST/UTC+1:00)
The European Stroke Organisation (ESO) Unveils Clinical Trials with Ground-Breaking Results at the Inaugural European Stroke Organisation Conference (ESOC 2015), Glasgow
Glasgow, UK, 17 April 2015 — — The European Stroke Organisation (ESO), at the first annual European Stroke Organisation Conference (ESOC 2015), in Glasgow, April 17-19, is pleased to announce the release of revolutionary medical trials and their results.
Today’s sessions which featured new large clinical trials and hot results (April 17, 10:30-12:00 and 14:00-15:00) are of significant impact to the global stroke community. Included among the various presentations, were the following industry studies:
PISCES – A Phase I Trial of CTX0E03 Human Neural Stem Cells in Ischaemic Stroke
The PISCES study was the first human study of human neural stem cells, given as an injection directly into the brain. The study included 11 male patients with long-term disability between 6 and 60 months after a stroke. The main purpose of the study was to determine safety. The final results are based on a minimum of 2 years of follow-up after the procedure. No cell-related adverse effects were seen. There were small improvements in neurological status and function in most participants, which were seen within a short time of the procedure and maintained throughout follow-up.
REVASCAT: Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
Four centers in Catalonia, Spain, randomized 206 patients with large anterior arterial occlusions to receive thrombectomy with the Solitaire device in addition to medical therapy (including IV t-PA if eligible) or medical therapy alone within 8 hours from the onset of stroke symptoms. Thrombectomy reduced the severity of disability over the range of the modified Rankin scale, led to higher rates of functional independence at 90 days (43.7% vs. 28.2%; adjusted odds ratio, 2.1; 95% CI, 1.1 to 4.0), reduced infarct size and increased quality of life at 3 months, without differences in mortality or symptomatic intracranial hemorrhage. REVASCAT contributes evidence to support the efficacy of neurovascular thrombectomy in patients with anterior circulation stroke who could be treated within 8 hours after the onset of symptoms.
Administration of Uric Acid in Acute Stroke: Results in Women and in Patients with Hyperglycemia
Giving stroke patients uric acid (a powerful antioxidant) along with standard clot-busting medication within 4.5 hours of first symptoms appears safe and effective at limiting disability, according to a recently Spanish multicenter study coordinated by Angel Chamorro, director of the Comprehensive Stroke Center, at Hospital Clinic in Barcelona, Spain. Although the study was not powered to provide definitive evidence of the value of this new treatment approach it showed highly significant benefits in relevant subgroups which were presented at the ESOC in Glasgow by investigators of the study. Thus, Laura Llull showed the significant benefits obtained by women after uric acid therapy, and which were attributed to their more limited antioxidant capacity than men. Likewise, Sergio Amaro showed the greater benefits obtained by patients with high blood sugar at stroke, a situation where oxidative stress is known to be significantly increased. According to these researchers uric acid may have a greater role in regulating human health and is a possible new approach to managing acute stroke that deserves validation in a larger confirmatory study.
The European Stroke Organisation (ESO) is a Pan-European society of stroke researchers, national and regional stroke societies and lay people organisations that was founded in December 2007. The aim of the ESO is to reduce the incidence and impact of stroke by changing the ways that stroke is viewed and treated. This can only be achieved by professional and public education, and by making institutional changes. The ESO provides assistance in achieving this goal and in harmonising stroke management across the whole of Europe. The ESO’s major objective is to improve and optimise the management of stroke in Europe by providing medical education to healthcare professionals and the lay public in Europe. By offering best practice approaches, the ESO’s goal is to harmonise stroke management in Europe. For more information, visit the website at: www.eso-stroke.org.